When asked what sustainability is, the first thing that comes to people's minds is the environment, especially the conservation of it, like fighting pollution and dealing with waste generation. However, the Brundtland reportThe 1987 UN report Our Common Future, which defined sustainable development. established that sustainability is notonly about the environment, and social and economicaspects should also be takenintoaccount. A sustainable solution has to be feasible and equally accessible to all for the three aspects to work together. Thus, this sustainable development page should be read along with Education and Human Practices pages to see how these considerations were integrated throughout our project.
Sustainable development that meets the needs of the present without compromising the ability of future generations to meet their own needs.
UN's Brundtland Commission, report "Our Common Future", 1987
However, the Sustainable Development Goals Report of 2026 shows that just over a third of the SDGs are on track to be achieved by the set deadline. Thus, we wanted to contribute to the SDGs in any way we could, to help bring them closer to reality. This is why we do not only list what our project contributes, but also where it and our team may do harm.
Figure 1. Photograph of the Lund University main building.
We built sustainability into every part of our project. This page brings it together in two steps: first, what AnTigone and our team contribute to SDG 3, 4, 5, 12 and 17; then, where they may work against these goals.
SDG Contributions
For each goal we explain why it matters for AnTigone and what we did about it.
"Ensure healthy lives and promote well-being for all at all ages"
This goal focuses on ensuring good health and promoting well-being for everyone, at all ages. Of the many targets under this goal, targets3.4"By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being", 3.7"By 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmes" and 3.8"Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all" (United Nations Department of Economic and Social Affairs, n.d.United Nations Department of Economic and Social Affairs. (n.d.). The 17 goals. Retrieved October 1, 2026, from https://sdgs.un.org/goalsGo to reference) tie in with the project: our potential product and project activities aim to promote mental health, ensure universal access to reproductive services, and provide better access to essential health-care services and to safe, effective, quality and affordable essential medicines for all.
Our project proposes a concept for a potential hormone-free option for people with PMOS-related hyperandrogenism. It is not a cure and would not treat the root cause of PMOS. It is designed to lower androgen activity in the gut, where androgens are reactivated and recirculated, and so to reduce hyperandrogenism symptoms in people for whom current treatments don't work or aren't tolerated.
How this relates to the targets:
Target 3.4 (mental health and well-being): Hyperandrogenism symptoms such as acne, excess hair growth, and hair loss affect self-esteem and mood in many patients (see the burden of depression and anxiety above). A treatment that reduces these symptoms could ease part of this burden, but we have not shown that it does.
Podcast The Sequence: 23 episodes so far, mixing interviews with iGEM teams around the world and fun facts from team members.
Note: Most events reached students already in science or engineering programs, mostly in Lund or Sweden in general. We measured attendance and feedback, not lasting learning, and we do not claim effects on employment. See more about the limitations later on this page under Inflictions.
"Achieve gender equality and empower all women and girls"
Goal 5 broadly addresses gender inequality and target 5.6"Ensure universal access to sexual and reproductive health and reproductive rights as agreed in accordance with the Programme of Action of the International Conference on Population and Development and the Beijing Platform for Action and the outcome documents of their review conferences" (United Nations Department of Economic and Social Affairs, n.d.United Nations Department of Economic and Social Affairs. (n.d.). The 17 goals. Retrieved October 1, 2026, from https://sdgs.un.org/goalsGo to reference) specifically focuses on achieving universal accessto sexual and reproductivehealth and reproductive rights, giving women the autonomy to make their own informed decisions regarding their reproductive health care. This fits our work partly: PMOS is an endocrine and reproductive condition, and ourawarenessworksupportsinformeddecisions and earlier diagnosis. We do not claim to change access to care itself.
The activities we ran under this goal were aimed at the people whose decisions about their own reproductive health are the most affected by poor information.
Using PMOS instead of PCOS (since May 2026): After the name change we used PMOS on our wiki, slides, socials and flyers, also next to “PCOS” so that it stayed recognisable.
PMOS Awareness Month (September). We ran mostly informal, low-barrier events, each with a PMOS introduction and from the second event onward a printed PMOS fact sheet, also introducing the name change.
"Ensure sustainable consumption and production patterns"
Goal 12 focuses on producing and consuming within environmental limits. It covers the efficient use of resources, the responsible management of chemicals and waste across their whole life cycle and also the provision of the information people need in order to make sustainable choices.
The indicators for target12.4"By 2020, achieve the environmentally sound management of chemicals and all wastes throughout their life cycle, in accordance with agreed international frameworks, and significantly reduce their release to air, water and soil in order to minimize their adverse impacts on human health and the environment" focuses on tracking countries' compliance with international agreements, the hazardous waste generated per capita and the proportion properly treated. Target12.5"By 2030, substantially reduce waste generation through prevention, reduction, recycling and reuse" focuses on reducing the wastes generated by systematically preventing, reducing, recycling and reusing whenever and wherever possible. Target12.8"By 2030, ensure that people everywhere have the relevant information and awareness for sustainable development and lifestyles in harmony with nature" focuses on ensuring that people everywhere have the relevant information and awareness for sustainable development and lifestyles grounded in harmony with nature (United Nations Department of Economic and Social Affairs, n.d.United Nations Department of Economic and Social Affairs. (n.d.). The 17 goals. Retrieved October 1, 2026, from https://sdgs.un.org/goalsGo to reference).
Biosafety by design (target12.4). Our biosafety committee worked in three layers: in-host control, environmental biocontainment and regulation.
In-host control: A hypoxia-responsive gut gate so that the enzyme is only expressed in the oxygen-poor gut, plus a proposed testosterone-sensing feedback loop combined with it as an AND gateA genetic circuit that switches on only when both inputs are present.. We chose a transient design that relies on redosing, because wild-type E. coli Nissle 1917A well-studied probiotic strain of E. coli. persists in the gut for weeks. The effect on resident gut bacteria remains an open question.
Environmental biocontainment: ΔdapA (DAP) auxotrophyMaking an organism unable to produce a substance it needs, so it can only grow when that substance is supplied. as the chosen primary strategy and a CRISPR kill switchA genetic circuit that kills the bacterium under defined conditions. driven by oxygen. Both are still design-stage. We also considered genetic stability, since mutation can restore growth.
Regulation: Chromosomal integrationInserting a gene into the bacterium's main genome rather than a plasmid, which makes it harder to pass on to other bacteria. is planned to limit gene transfer, and we reviewed the EU rules on contained useWork with genetically modified organisms inside closed facilities such as laboratories., release and medicinal use, the EMAThe European Medicines Agency, which evaluates and approves medicines in the EU. environmental risk assessment guideline and the Cartagena ProtocolThe Cartagena Protocol on Biosafety to the Convention on Biological Diversity is an international agreement which aims to ensure the safe handling, transport and use of living modified organisms.
Chemicals in our own lab (target 12.4): We used green chemicals where possible and avoided CMR reagentsChemicals that are carcinogenic, mutagenic or toxic to reproduction., with testosterone the only one that was necessary. We also avoided other toxic chemicals such as ethidium bromideA dye used to see DNA in gels. It is a suspected mutagen., but some had to be used, such as imidazole and NiClNickel chloride, a nickel salt used to charge His-tag purification columns.. Changing kanamycinAn antibiotic used in the lab to select bacteria that carry a matching resistance gene. to ampicillin or spectinomycin made waste disposal safer.
Transparency is the currency. Transparency is what you should focus on.
Magdalena Nour, CEO of Vati of Sweden, in conversation with iGEM Lund, 8 September 2026
We therefore name where our team and our product may work against the goals, why we accept it, and what we do about it. The first group comes from how we as a team work, the second from a hypothetical product.
Team-Based Inflictions
These impacts come from how we, as a student team, run our project: where we teach, how we work in the lab, and how we travel.
Education Reach
Inflicting SDG 4: “Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all.”
SDG 4 asks for inclusive and equitable quality education.
Our reach has stayed narrow in geography, language and audience. Our events took place in Lund (BioCamp, two gymnasium workshops, PMOS Awareness Month, the K-Guild Study Night and the sustainability lecture), in Strängnäs (Rays for Excellence) and in Malmö (library). Most materials are English-only, the podcast is on Spotify, which is not accessible everywhere, and most participants were students already in science programs. We did not measure lasting learning.
This is how we are dealing with it:
English is our primary and mostly only language. That is a limitation, but simultaneously also the most inclusive way. We introduced more languages for the material that mattered most, children's books, but besides that we did not further focus on having multiple translations, but we would call that defensible.
Our children's book exists in six languages, Chinese, Spanish, German, Swedish, English, and Italian, genuinely global reach for that specific material, not just an English product.
Our podcast, The Sequence, is built specifically to pull in perspectives from outside our own bubble: we've talked with other iGEM teams from e.g. Brazil, Canada, Mexico, Taiwan, and India about their projects, struggles, and journeys. Spotify itself has accessibility limits, but the content is deliberately not Sweden- or Europe-only.
The concentration around Lund is partly a deliberate choice, not only a gap: as a small student team, we can have a real, measurable effect on the community immediately around us in a way we couldn't replicate by spreading thin across a global audience we don't have the capacity to actually serve. We think it's more honest to say we chose local depth over global breadth than to claim we achieved both.
Why we accept it: spreading the same effort across many places would have meant less quality everywhere.
Wet Lab Safety
Inflicting SDG 8.8: “Protect labor rights and promote safe and secure working environments for all workers […]”
Risk assessment for every activity, safety data sheets accessible for every chemical used.
Testosterone, a controlled substanceA drug whose possession and use are legally regulated. also used in doping, has its own training and is handled only by dedicated people.
Emergency procedures covered: eye washes, safety showers, fire extinguishers and blankets, emergency numbers, first aid for injuries.
Basic lab rule: never work alone in the lab.
The training content, waste handling, equipment and all risk assessments are on our Lab Safety page. The safety of the engineered bacteria themselves is on Biosafety: in-host control, environmental biocontainment and GMO regulations.
Why we accept it: the enzymes had to be tested in a wet lab, but the risks were reduced with the actions above.
Travel & Climate
Inflicting SDG 13: “Take urgent action to combat climate change and its impacts.”
The usual answer to flight emissions is carbon offsetsPaying for projects that cut emissions elsewhere to balance one's own emissions., after which the buyer then treats their emissions as canceled.
Figure 2. Receipt for our one-time donation of £330 to Opportunity Green on 18 October 2026.
Product-Based Inflictions
These impacts concern the hypothetical product. They describe what could happen if it were ever developed.
Access & Affordability
Inflicting SDG 3.8: “Achieve universal health coverage […] and access to safe, effective, quality and affordable essential medicines and vaccines for all” and SDG 10 (goal level): “Reduce inequality within and among countries.”
Target 3.8 asks for universal health coverage and access to safe, effective, quality and affordable essential medicines. SDG 10 asks for reduced inequality within and among countries. AnTigone could deepen inequality if it were ever developed. A product that needs a diagnosis, a prescription, specialized manufacturing and possibly cold storage first reaches the people who already have the best access to care, and PMOS is under-diagnosed everywhere.
How we're dealing with it: we are not claiming access. We explore the oral capsule format, which is easier to store and administer than injections or infusions, and we did a first price estimation and target in the Economical Assessment. We do not know what it would cost to manufacture or distribute.
Why we accept it: AnTigone is a proof of concept, and a student team cannot solve pricing, distribution and regulation.
Environmental & Biocontainment Footprint
Inflicting SDG 12.4: “[…] achieve the environmentally sound management of chemicals and all wastes throughout their life cycle […]” and SDG 6.3: “[…] improve water quality by reducing pollution […]”
Layered design: a hypoxia-responsive gut gate, ΔdapA auxotrophy and a CRISPR kill switch, with chromosomal integration to limit gene transfer. We also considered genetic stability, since mutation can undo containment. See Biosafety page.
Akin, H., Rose, K. M., Scheufele, D. A., Simis-Wilkinson, M., Brossard, D., Xenos, M. A., & Corley, E. A. (2017). Mapping the landscape of public attitudes on synthetic biology. BioScience, 67(3), 290–300. https://doi.org/10.1093/biosci/biw171
Bahri Khomami, M., Shorakae, S., Hashemi, S., Harrison, C. L., Piltonen, T. T., Romualdi, D., Tay, C. T., Teede, H. J., Vanky, E., & Mousa, A. (2024). Systematic review and meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Nature Communications, 15(1), Article 5591. https://doi.org/10.1038/s41467-024-49749-1
Barlek, M. H., Rouan, J. R., Wyatt, T. G., Helenowski, I., & Kibbe, M. R. (2022). The persistence of sex bias in high-impact clinical research. Journal of Surgical Research, 278, 364–374. https://doi.org/10.1016/j.jss.2022.04.077
Cooney, L. G., Lee, I., Sammel, M. D., & Dokras, A. (2017). High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: A systematic review and meta-analysis. Human Reproduction, 32(5), 1075–1091. https://doi.org/10.1093/humrep/dex044
European Parliament and Council of the European Union. (2001). Directive 2001/18/EC on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC. Official Journal of the European Communities, L 106, 1–39. https://eur-lex.europa.eu/eli/dir/2001/18/oj
Forslund, M., Melin, J., Joham, A. E., Piltonen, T. T., Rees, D. A., & Teede, H. J. (2026). Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk. Journal of Internal Medicine. Advance online publication. https://doi.org/10.1111/joim.70156
Gibson-Helm, M., Teede, H., Dunaif, A., & Dokras, A. (2017). Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 102(2), 604–612. https://doi.org/10.1210/jc.2016-2963
Joeres-Nguyen-Xuan, T. H., Boehm, S. K., Joeres, L., Schulze, J., & Kruis, W. (2010). Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers. Inflammatory Bowel Diseases, 16(2), 256–262. https://doi.org/10.1002/ibd.21042
Kidd, K. A., Blanchfield, P. J., Mills, K. H., Palace, V. P., Evans, R. E., Lazorchak, J. M., & Flick, R. W. (2007). Collapse of a fish population after exposure to a synthetic estrogen. Proceedings of the National Academy of Sciences, 104(21), 8897–8901. https://doi.org/10.1073/pnas.0609568104
Klaica, M., & Jirsa, F. (2022). 17α-Ethinylestradiol (EE2): Concentrations in the environment and methods for wastewater treatment – An update. RSC Advances, 12(20), 12794–12805. https://doi.org/10.1039/D2RA00915C
Koide, R., Lettenmeier, M., Akenji, L., Toivio, V., Amellina, A., Khodke, A., Watabe, A., & Kojima, S. (2021). Lifestyle carbon footprints and changes in lifestyles to limit global warming to 1.5 °C, and ways forward for related research. Sustainability Science, 16(6), 2087–2099. https://doi.org/10.1007/s11625-021-01018-6
Liu, J., Zhang, Y., Huang, Y., Li, X., Huang, X., Xing, X.-H., & Zhang, C. Y. (2026). Enabling clinical translation of oral probiotics through formulation engineering and scalable manufacturing. Biotechnology Journal, 21(6), Article e70253. https://doi.org/10.1002/biot.70253
Panchpuri, M., Kisku, A., Painuli, R., Pant, G., & Kumar, C. (2026). Polycystic ovary syndrome (PCOS): Current insights, emerging therapeutics, and future treatment strategies. Inflammopharmacology, 34(2), 1005–1040. https://doi.org/10.1007/s10787-026-02117-5
Teede, H. J., Khomami, M. B., Morman, R., Laven, J. S. E., Joham, A. E., Costello, M. F., Patil, M., Rees, D. A., Berry, L., Cree, M. G., Zhao, H., Norman, R. J., Dokras, A., Piltonen, T., Amao, S., Amiri, M., Andrews, C., Arcari, A., Arlt, W., . . . Zhang, Y. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: A multistep global consensus process. The Lancet, 407(10545), 2329–2339. https://doi.org/10.1016/s0140-6736(26)00717-8
Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 108(10), 2447–2469. https://doi.org/10.1210/clinem/dgad463
United Nations Department of Economic and Social Affairs. (n.d.). The 17 goals. Retrieved October 1, 2026, from https://sdgs.un.org/goals
Wegmann, U., Carvalho, A. L., Stocks, M., & Carding, S. R. (2017). Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect. Scientific Reports, 7, Article 2294. https://doi.org/10.1038/s41598-017-02591-6
Wilkinson, J. L., Boxall, A. B. A., Kolpin, D. W., Leung, K. M. Y., Lai, R. W. S., Galbán-Malagón, C., Adell, A. D., Mondon, J., Metian, M., Marchant, R. A., Bouzas-Monroy, A., Cuni-Sanchez, A., Coors, A., Carriquiriborde, P., Rojo, M., Gordon, C., Cara, M., Moermond, M., Luarte, T., . . . Teta, C. (2022). Pharmaceutical pollution of the world's rivers. Proceedings of the National Academy of Sciences, 119(8), Article e2113947119. https://doi.org/10.1073/pnas.2113947119